4.5 Review

Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?

Journal

PHARMACEUTICAL RESEARCH
Volume 37, Issue 1, Pages -

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-019-2745-x

Keywords

biopharmaceutical; intraperitoneal; macromolecule; pharmacokinetics; small molecule

Funding

  1. NIH [1R01NS106879]
  2. AHA [14BGIA20380826]
  3. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS106879] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Intraperitoneal (IP) route of drug administration in laboratory animals is a common practice in many in vivo studies of disease models. While this route is an easy to master, quick, suitable for chronic treatments and with low impact of stress on laboratory rodents, there is a common concern that it may not be an acceptable route for drug administration in experimental studies. The latter is likely due to sparsity of information regarding pharmacokinetics of pharmacological agents and the mechanisms through which agents get systemic exposure after IP administration. In this review, we summarize the main mechanisms involved in bioavailability of IP administered drugs and provide examples of pharmacokinetic profiles for small and large molecules in comparison to other routes of administration. We conclude with a notion that IP administration of drugs in experimental studies involving rodents is a justifiable route for pharmacological and proof-of-concept studies where the goal is to evaluate the effect(s) of target engagement rather than properties of a drug formulation and/or its pharmacokinetics for clinical translation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available